• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home Uncategorized

2 Minute Medicine Rewind: May 25 – June 1

bys25qthea
June 22, 2013
in Uncategorized
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

May 25 – June 1, 2013

In this section, we will highlight the some of the most high-impact studies, updates, and analyses published in medicine during the past week.

Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer and

Acquired Resistance to Crizotinib from a Mutation in CD74–ROS1

This phase 3, open-label trial compared crizotinib with chemotherapy in 347 patients with locally advanced or metastatic ALK-positive lung cancer who had failed prior therapy. There was an improvement in progression free survival (7.7 months vs. 3.0 months, p < 0.001), however there has been no overall mortality benefit to be seen (HR 1.02). An acquired CD74–ROS1 rearrangement was identified in a patient that had an initial dramatic response to crizotinib and is shown to block drug binding.

Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study

In this phase 2 RCT of selumetinib and dacabazine vs. dacabizine alone for the treatment of BRAF+ melanoma, patients receiving zelumetinib had a statistically significant improvement in progression-free survival (5.6 months vs. 3.0 months, p = 0.021), however there was no statistically significant improvement in overall survival (13.9 months vs. 10.5 months, p = 0.39).

RELATED REPORTS

Momelotinib reduces symptom burden compared to danazol in patients with myelofibrosis

Machine renal perfusion reduces delayed graft function after transplantation

COVID-19 mRNA vaccines are safe and effective in children aged 5 to 11 years

Outcomes of Medical Emergencies on Commercial Airline Flights

In this study, investigators retrospectively looked at the records of in-flight medical emergencies and found that the most common problems were syncope (37.4%), respiratory symptoms (12.1%), and nausea or vomiting (9.5%). There was 1 medical emergency per 604 flights, with 25.8% resulting in transport to a hospital, 8.6% admitted to a hospital, and 0.3% dying. 7.3% of airborne medical emergencies required diversion of the flight.

Treatment of low bone density in young people with cystic fibrosis: a multicentre, prospective, open-label observational study of calcium and calcifediol followed by a randomised placebo-controlled trial of alendronate

In this multicenter RCT, 43 (25%) patients with cystic fibrosis and low bone mineral density were observed with 5% or more improved bone marrow density after receiving 12 months of calcium and calcifediol. Patients subsequently randomized to alendonate had 16.3% more bone mineral density increase vs. 3.1% in placebo.

By David Ouyang

Previous Post

The COPERNICUS trial: Beta-blockers in severe chronic heart failure [Classics Series]

Next Post

Gastric bypass surgery reduces cardio-metabolic risk factors

RelatedReports

JAK2 and TET2 mutations temporally linked with myeloproliferative disorder outcomes
Chronic Disease

Momelotinib reduces symptom burden compared to danazol in patients with myelofibrosis

February 8, 2023
State policies for organ donation may be largely ineffective
Chronic Disease

Machine renal perfusion reduces delayed graft function after transplantation

February 8, 2023
Compliance-linked incentives increase infant immunizations rates in rural India
Infectious Disease

COVID-19 mRNA vaccines are safe and effective in children aged 5 to 11 years

February 8, 2023
Adolescent mothers in protective care more likely to have their children placed in care
Chronic Disease

Study details side effects of alpha-2-adrenergic agonists for treating ADHD in preschool children

February 8, 2023
Next Post
Gastric bypass surgery reduces cardio-metabolic risk factors

Gastric bypass surgery reduces cardio-metabolic risk factors

Bariatric surgery is an effective option for weight loss and glycemic control

Bariatric surgery is an effective option for weight loss and glycemic control

Prophylactic platelet transfusions prevent bleeding in hematologic cancers

Eculizumab treats atypical hemolytic-uremic syndrome

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Momelotinib reduces symptom burden compared to danazol in patients with myelofibrosis
  • Machine renal perfusion reduces delayed graft function after transplantation
  • COVID-19 mRNA vaccines are safe and effective in children aged 5 to 11 years
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options